<code id='84201A8A40'></code><style id='84201A8A40'></style>
    • <acronym id='84201A8A40'></acronym>
      <center id='84201A8A40'><center id='84201A8A40'><tfoot id='84201A8A40'></tfoot></center><abbr id='84201A8A40'><dir id='84201A8A40'><tfoot id='84201A8A40'></tfoot><noframes id='84201A8A40'>

    • <optgroup id='84201A8A40'><strike id='84201A8A40'><sup id='84201A8A40'></sup></strike><code id='84201A8A40'></code></optgroup>
        1. <b id='84201A8A40'><label id='84201A8A40'><select id='84201A8A40'><dt id='84201A8A40'><span id='84201A8A40'></span></dt></select></label></b><u id='84201A8A40'></u>
          <i id='84201A8A40'><strike id='84201A8A40'><tt id='84201A8A40'><pre id='84201A8A40'></pre></tt></strike></i>

          Home / hotspot / comprehensive

          comprehensive


          comprehensive

          author:hotspot    Page View:2

          Editor’s note: A recording of the event is embedded below.

          After a few go-go years, the early-stage biotech market has cooled considerably. Two VCs will weigh in on what distinguishes great science from bad investments.

          advertisement

          Featured Speakers

          • Irena Melnikova, Ph.D., partner, Pfizer Ventures
          • Rakhshita Dhar, senior director, venture investments, Leaps by Bayer
          • Frank S. David, M.D., Ph.D., managing director, Pharmagellan (moderator)

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In